press release: Vermillion and ASPiRA LABs Applaud the FDA’s Position on Ovarian Cancer Screening Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, September 09, 2016

press release: Vermillion and ASPiRA LABs Applaud the FDA’s Position on Ovarian Cancer Screening



press release

Vermillion and ASPiRA LABs Applaud the FDA's Position on Ovarian Cancer Screening

AUSTIN, Texas, Sept. 9, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced its support for the recent US Food and Drug Administration (FDA) safety communication which recommends against the use of any screening tests for ovarian cancer.
Earlier this week, the FDA announced that it is alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests. The Agency stated that it is especially concerned about delaying effective preventive treatments for women who show no symptoms, but who are still at increased risk for developing ovarian cancer. 
As the medical community knows, ASPiRA LABs' FDA cleared technologies, OVA1® and Overa, are NOT screening tests. OVA1/Overa are FDA cleared technologies to assess risk of ovarian cancer malignancy for women who present with a pelvic mass and are planned for surgery........

0 comments :

Post a Comment

Your comments?